AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United ...

Patterson + Sheridan has welcomed Kristian Sullivan as counsel. He is based in the firm’s Houston office.

The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.

Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

Axsome Therapeutics (NASDAQ:AXSM) stock rallied 15% in morning trading on news it has settled patent litigation with Teva (NYSE:TEVA) over its antidepressant drug Auvelity. Axsome (NASDAQ:AXSM) had ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.1 billion market cap biopharmaceutical company with impressive 91% gross profit margins, has reached a settlement agreement with Teva ...

The court also disqualified in-house patent counsel’s legal department and outside counsel because in-house patent counsel’s acquired knowledge was imputed (see Imputed Conflicts above). (837 ...

I tried to apply for a title over the said land, however, I was informed by the concerned government agency that a patent title was already issued ... Government agencies like the Department of ...

It likewise presents a ripe opportunity for the United States ... to report a patent monetization firm, IP Edge LLC, to an ethics committee in Texas and the U.S. Department of Justice after ...

The policies of the last four years, ranging from technology giveaways to taxpayer-funded patent infringement ... It’s not just the Biden-Harris Justice Department discovering sweeping new ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy. The litigation ...